The myasthenia gravis paradox: why this rare disease correlates with extended lifespan

A population-based analysis across four U.S. states uncovered an unexpected survival advantage in myasthenia gravis patients, who show a mean age at death 4.8 years higher than the general population, compared to a 12.4-year deficit in multiple sclerosis patients—a similar but more severe autoimmune neurological condition. The mechanistic explanation remains elusive, though researchers identify several plausible threads worth pulling. Unlike MS, myasthenia gravis does not cause progressive neurodegeneration or structural demyelination; it selectively disrupts neuromuscular transmission, allowing many patients to achieve meaningful functional recovery with treatment. The drugs used—acetylcholinesterase inhibitors and immunosuppressants—present an intriguing angle; acetylcholinesterase inhibitors show cognitive benefits in Alzheimer's disease and improved pulmonary function in aged mice, though broader systemic effects remain unclear. A third hypothesis centers on the intensity of clinical monitoring: myasthenia gravis diagnosis triggers close physician oversight and sustained lifestyle counsel, potentially accelerating detection and treatment of age-related comorbidities before they compound mortality risk. Notably, MG populations carry higher reported burdens of hypertension, diabetes, and pulmonary disease than MS populations, yet still demonstrate superior longevity—a paradox that hints at forces operating beyond conventional comorbidity models.